PEG-PCL based micelle hydrogels as oral docetaxel delivery systems for breast cancer therapy

Biomaterials

Volumn 35, Issue 25, 2014, Pages 6972-6985

  Wang, YuJun ^a   Chen, LiJuan ^a   Tan, LiWei ^a   Zhao, Qian ^a   Luo, Feng ^a   Wei, YuQuan ^a   Qian, ZhiYong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Breast cancer; Docetaxel; Hydrogel; Micelles; Oral delivery

Indexed keywords

BIOCHEMISTRY; CELL DEATH; DIFFUSION IN LIQUIDS; DISEASES; DRUG DELIVERY; DRUG PRODUCTS; MICELLES; ONCOLOGY; PH;

BREAST CANCER; DOCETAXEL; GASTROINTESTINAL TRACT; IMMUNOHISTOCHEMICAL STUDIES; ORAL BIOAVAILABILITIES; ORAL DELIVERY; PH-RESPONSIVE HYDROGELS; PHARMACOKINETIC STUDIES;

HYDROGELS;

DOCETAXEL; MACROGOL; POLYCAPROLACTONE; ANTINEOPLASTIC AGENT; HYDROGEL; MACROGOL DERIVATIVE; MICELLE; NANOPARTICLE; POLY(EPSILON-CAPROLACTONE)-B-POLY(ETHYLENEGLYCOL)-B-POLY(EPSILON-CAPROLACTONE); POLYESTER; TAXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG PENETRATION; DRUG SOLUBILITY; HYDROGEL; HYDROGEN BOND; IMMUNOREACTIVITY; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MICELLE; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PH; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; SMALL INTESTINE ABSORPTION; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; FEMALE; ORAL DRUG ADMINISTRATION; PROCEDURES; SPRAGUE DAWLEY RAT; X RAY DIFFRACTION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; FEMALE; HYDROGELS; HYDROGEN-ION CONCENTRATION; MICE; MICE, INBRED BALB C; MICELLES; NANOPARTICLES; PARTICLE SIZE; POLYESTERS; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; TAXOIDS; X-RAY DIFFRACTION;

EID: 84902083117     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.04.099     Document Type: Article

References (39)

1. Vassilomanolakis M., Koumakis G., Barbounis V., Demiri M., Panopoulos C., Chrissohoou M., et al. First-line chemotherapy with docetaxel and cisplatin in metastatic breast cancer. Breast 2005, 14:136-141.
2. Campora E., Colloca G., Ratti R., Addamo G., Coccorullo Z., Venturino A., et al. Docetaxel for metastatic breast cancer: two consecutive phase II trials. Anticancer Res 2008, 28:3993-3995.
3. Bhalla K.N. Microtubule-targeted anticancer agents and apoptosis. Oncogene 2003, 22:9075-9086.
4. Rowinsky E.K., Donehower R.C. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther 1991, 52:35-84.
5. Gao K., Sun J., Liu K., Liu X.H., He Z.G. Preparation and characterization of a submicron lipid emulsion of docetaxel: submicron lipid emulsion of docetaxel. Drug Dev Ind Pharm 2008, 34:1227-1237.
6. Kuppens I., Bosch T.M., van Maanen M.J., Rosing H., Fitzpatrick A., Beijnen J.H., et al. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Cancer Chemother Pharmacol 2005, 55:72-78.
7. Engels F.K., Mathot R.A.A., Verweij J. Alternative drug formulations of docetaxel: a review. Anticancer Drugs 2007, 18:95-103.
8. Nuijen B., Bouma M., Schellens J.H., Beijnen J.H. Progress in the development of alternative pharmaceutical formulations of taxanes. Invest New Drugs 2001, 19:143-153.
9. Song H., Geng H.Q., Ruan J., Wang K., Bao C.C., Wang J., et al. Development of polysorbate 80/phospholipid mixed micellar formation for docetaxel and assessment of its invivo distribution in animal models. Nanoscale Res Lett 2011, 6.
10. Mei L., Zhang Y.Q., Zheng Y., Tian G., Song C.X., Yang D.Y., et al. Anovel docetaxel-loaded poly (epsilon-caprolactone)/pluronic F68 nanoparticle overcoming multidrug resistance for breast cancer treatment. Nanoscale Res Lett 2009, 4:1530-1539.
11. Ernsting M.J., Tang W.L., MacCallum N.W., Li S.D. Preclinical pharmacokinetic, biodistribution, and anti-cancer efficacy studies of a docetaxel-carboxymethylcellulose nanoparticle in mouse models. Biomaterials 2012, 33:1445-1454.
12. Mikhail A.S., Allen C. Poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles containing chemically conjugated and physically entrapped docetaxel: synthesis, characterization, and the influence of the drug on micelle morphology. Biomacromolecules 2010, 11:1273-1280.
13. Elsabahy M., Perron M.E., Bertrand N., Yu G.E., Leroux J.C. Solubilization of docetaxel in poly(ethylene oxide)-block-poly(butylene/styrene oxide) micelles. Biomacromolecules 2007, 8:2250-2257.
14. Koo A.N., Min K.H., Lee H.J., Lee S.U., Kim K., Kwon I.C., et al. Tumor accumulation and antitumor efficacy of docetaxel-loaded core-shell-corona micelles with shell-specific redox-responsive cross-links. Biomaterials 2012, 33:1489-1499.
15. Baker S.D., Sparreboom A., Verweij J. Clinical pharmacokinetics of docetaxel - recent developments. Clin Pharmacokinet 2006, 45:235-252.
16. Goh B.C., Lee S.C., Wang L.Z., Fan L., Guo J.Y., Lamba J., et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. JClin Oncol 2002, 20:3683-3690.
17. Bardelmeijer H.A., Ouwehand M., Buckle T., Huisman M.T., Schellens J.H.M., Beijnen J.H., et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 2002, 62:6158-6164.
18. Behrens I., Pena A.I., Alonso M.J., Kissel T. Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport. Pharm Res 2002, 19:1185-1193.
19. Soppimath K.S., Kulkarni A.R., Aminabhavi T.M. Chemically modified polyacrylamide-g-guar gum-based crosslinked anionic microgels as pH-sensitive drug delivery systems: preparation and characterization. JControl Release 2001, 75:331-345.
20. Sadeghi M., Hosseinzadeh H. Synthesis of starch-poly(sodium acrylate-co-acrylamide) superabsorbent hydrogel with salt and pH-responsiveness properties as a drug delivery system. JBioact Compat Polym 2008, 23:381-404.
21. Wu W., Wang D.S. Afast pH-responsive IPN hydrogel: synthesis and controlled drug delivery. React Funct Polym 2010, 70:684-691.
22. Gou M.L., Zheng L., Peng X.Y., Men K., Zheng X.L., Zeng S., et al. Poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) (PCL-PEG-PCL) nanoparticles for honokiol delivery invitro. Int J Pharm 2009, 375:170-176.
23. Tan L.W., Xu X., Song J., Luo F., Qian Z.Y. Synthesis, characterization, and acute oral toxicity evaluation of pH-sensitive hydrogel based on MPEG, poly(epsilon-caprolactone), and itaconic acid. Biomed Res Int 2013, 239838.
24. Wang C., Wang Y.J., Wang Y.J., Fan M., Luo F., Qian Z.Y. Characterization, pharmacokinetics and disposition of novel nanoscale preparations of paclitaxel. Int J Pharm 2011, 414:251-259.
25. Wang K., Xu X., Wang Y.J., Yan X., Guo G., Huang M.J., et al. Synthesis and characterization of poly(methoxyl ethylene glycol-caprolactone-co-methacrylic acid-co-poly(ethylene glycol) methyl ether methacrylate) pH-sensitive hydrogel for delivery of dexamethasone. Int J Pharm 2010, 389:130-138.
26. Masuda M., Hirakawa N., Nakashima T., Kuratomi Y., Komiyama S. Cyclin D1 overexpression in primary hypopharyngeal carcinomas. Cancer - Am Cancer Soc 1996, 78:390-395.
27. Feng S.S., Mei L., Anitha P., Gan C.W., Zhou W.Y. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of docetaxel. Biomaterials 2009, 30:3297-3306.
28. Aisner J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Health Syst Pharm 2007, 64:S4-S7.
29. Van Kruiningen H.J., West A.B., Freda B.J., Holmes K.A. Distribution of Peyer's patches in the distal ileum. Inflamm Bowel Dis 2002, 8:180-185.
30. Huang Y.W., Zeng M., Ren J., Wang J., Fan L.R., Xu Q.Y. Preparation and swelling properties of graphene oxide/poly(acrylic acid-co-acrylamide) super-absorbent hydrogel nanocomposites. Colloid Surf A 2012, 401:97-106.
31. Peng J.R., Qi T.T., Liao J.F., Fan M., Luo F., Li H., et al. Synthesis and characterization of novel dual-responsive nanogels and their application as drug delivery systems. Nanoscale 2012, 4:2694-2704.
32. Malingre M.M., Richel D.J., Beijnen J.H., Rosing H., Koopman F.J., Huinink T.B., et al. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. JClin Oncol 2001, 19:1160-1166.
33. Yan Y.D., Kim D.H., Sung J.H., Yong C.S., Choi H.G. Enhanced oral bioavailability of docetaxel in rats by four consecutive days of pre-treatment with curcumin. Int J Pharm 2010, 399:116-120.
34. Lo Y.L., Huang J.D. Effects of sodium deoxycholate and sodium caprate on the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. Biochem Pharmacol 2000, 59:665-672.
35. Anderberg E.K., Lindmark T., Artursson P. Sodium caprate elicits dilatations in human intestinal tight junctions and enhances drug absorption by the paracellular route. Pharm Res 1993, 10:857-864.
36. Krug S.M., Amasheh M., Dittmann I., Christoffel I., Fromm M., Amasheh S. Sodium caprate as an enhancer of macromolecule permeation across tricellular tight junctions of intestinal cells. Biomaterials 2013, 34:275-282.
37. Yoo M.K., Kang S.K., Choi J.H., Park I.K., Na H.S., Lee H.C., et al. Targeted delivery of chitosan nanoparticles to Peyer's patch using M cell-homing peptide selected by phage display technique. Biomaterials 2010, 31:7738-7747.
38. Ferreiro M.G., Tillman L.G., Hardee G., Bodmeier R. Alginate/poly-L-lysine microparticles for the intestinal delivery of antisense oligonucleotides. Pharm Res 2002, 19:755-764.
39. Lauro M.R., Torre M.L., Maggi L., De Simone F., Conte U., Aquino P.R. Fast- and slow-release tablets for oral administration of flavonoids: rutin and quercetin. Drug Dev Ind Pharm 2002, 28:371-379.